Rowland Carmichael Advisors’s VanEck Biotech ETF BBH Stock Holding History

Rowland Carmichael Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$10K	Buy	+60	New	+$9.88K	﹤0.01%	352

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rowland Carmichael Advisors's BBH Position: Q4 2020 in Review

Rowland Carmichael Advisors opened a new position in VanEck Biotech ETF (BBH) in Q4 2020: 60 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #352 among its holdings.

108 funds tracked by Wall St. Rank hold BBH as of Q4 2020.

Rowland Carmichael Advisors held 60 shares of VanEck Biotech ETF worth $10K as of Q4 2020.
VanEck Biotech ETF was a new Rowland Carmichael Advisors position in Q4 2020.
VanEck Biotech ETF made up ﹤0.01% of Rowland Carmichael Advisors's portfolio in Q4 2020, its #352 holding.
108 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2020.

Based on Rowland Carmichael Advisors's 13F filing for Q4 2020, filed 15 Jan 2021.